



FINANCIAL TEAR SHEET

Corporate Profile

Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company's close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases such as Sanfilippo disorder, Batten disease, Fanconi anemia and other rare disorders.

Primary IR Contact

Andre'a Lucca
 Director of Communications
 PlasmaTech
 Biopharmaceuticals, Inc.
Phone: 212-786-6208
E-mail:
 alucca@plasmatechbio.com

Stock Performance

ABEO (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	\$16.08
Change (%)	▼ 0.08 (0.43%)
Volume	255,583
52 Week Low	\$4.05
Market Cap	\$755,420,401
Rolling EPS	-0.65
PE Ratio	0
Shares Outstanding	46,775,257



Data as of November 22, 2017 12:40 p.m. ET

Recent Press Releases & Upcoming Events

November 15, 2017
Abeona Reports Third Quarter 2017
Financial Results and Recent Business
Highlights

November 9, 2017
Abeona Enrolls First Subject in Spain in
Ongoing Phase 1/2 Clinical Trial in MPS
IIIA

October 19, 2017
Abeona Announces Closing of \$92 Million
Underwritten Public Offering and Full
Exercise of Underwriters' Option to
Purchase Additional Shares

Date	Title
November 24, 2017 through November 26, 2017	BDFA Family Conference Location Pittsburgh, PA

SEC Filings

Filing Date	Form
November 14, 2017	10-Q
November 14, 2017	S-8
October 19, 2017	8-K
October 17, 2017	8-K

Corporate Governance

Data provided by Nasdaq. Minimum 15 minutes delayed.